Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Joincare Pharmaceutical Group Industry Co's average EBITDA Per Share Growth Rate was -6.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 6.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Joincare Pharmaceutical Group Industry Co was 80.90% per year. The lowest was -24.60% per year. And the median was 10.35% per year.
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Joincare Pharmaceutical Group Industry Co 3-Year EBITDA Growth Rate Related Terms
XSWX:JCARE vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Joincare Pharmaceutical Group Industry Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joincare Pharmaceutical Group Industry Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Joincare Pharmaceutical Group Industry Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Joincare Pharmaceutical Group Industry Co's 3-Year EBITDA Growth Rate falls into.
Joincare Pharmaceutical Group Industry Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Joincare Pharmaceutical Group Industry Co and its competitors. According to the industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #999999 out of 809 companies in the Drug Manufacturers industry.
Is Joincare Pharmaceutical Group Industry Co's 3-Year EBITDA Growth Rate too high?
Joincare Pharmaceutical Group Industry Co's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Joincare Pharmaceutical Group Industry Co ranks #999999 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #999999 out of 809 companies for 3-Year EBITDA Growth Rate. This places Joincare Pharmaceutical Group Industry Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Joincare Pharmaceutical Group Industry Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joincare Pharmaceutical Group Industry Co's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) has a current 3-Year EBITDA Growth Rate of 0.00%. The stock's GF Value™ is $9.20, compared to a current price of $8.00 — trading 13% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (XSWX:JCARE), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued.
The current stock price of $8.00 is trading 13% below its estimated GF Value™ of $9.20.
Key valuation signals for XSWX:JCARE:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: $9.20 vs. price of $8.00 (13% below fair value)
No single metric tells the full story. See the XSWX:JCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
80GF Score
Get the complete analysis for XSWX:JCARE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:JCARE has been successfully added to your 
